Unknown

Dataset Information

0

Immunotherapy with canarypox vaccine and interleukin-2 for HIV-1 infection: termination of a randomized trial.


ABSTRACT:

Objectives

To determine whether immunotherapy of chronic HIV-1 infection can prevent or attenuate viremia upon antiviral discontinuation.

Design

This was a Phase II randomized, partially double blinded, 2x2 factorial study of three steps of 12 wk/step. Step I involved four groups: (1) vaccine placebo, (2) vaccine (ALVAC, vCP1452), (3) placebo + interleukin 2 (IL-2), and (4) vaccine + IL-2. Step II involved a 12-wk diagnostic treatment interruption (DTI). Step III involved an extension of the DTI for an additional 12 wk.

Setting

The Weill-Cornell General Clinical Research Center.

Participants

Chronically infected HIV-1 positive adults with undetectable HIV-1 levels and > 400 CD4+ T cells/microl.

Interventions

An HIV canarypox vaccine (vCP1452) and vaccine placebo, administered every 4 wk for four doses, and low-dose IL-2 administered daily for 12-24 wk.

Outcome measures

Primary endpoints: (1) Proportion of participants with undetectable plasma HIV RNA during trial Step II, (2) mean log10 HIV RNA copies/ml ([HIV]) from weeks 21-25, and (3) proportion of individuals eligible for trial Step III.

Results

44 participants were randomized, but 16 withdrew or were withdrawn before completing Step II. As all participants underwent viral relapse in Step II, the study was terminated after 28 participants completed Step II. Among the four groups, there was no difference in mean [HIV] or the proportion of individuals with < log10 4.48 HIV; no difference between the mean [HIV] of the two groups that received ALVAC (n = 17) versus placebo (n = 11); and no significant difference between the mean [HIV] of the two groups that received IL-2 (n = 11) versus placebo (n = 17).

Conclusions

Neither ALVAC (vCP1452) nor low-dose daily IL-2 nor their combination prevented the relapse of viremia upon discontinuation of antiviral therapy.

SUBMITTER: Smith KA 

PROVIDER: S-EPMC1783674 | biostudies-literature | 2007 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Immunotherapy with canarypox vaccine and interleukin-2 for HIV-1 infection: termination of a randomized trial.

Smith Kendall A KA   Andjelic Sofija S   Popmihajlov Zoran Z   Kelly-Rossini Liza L   Sass Aquanette A   Lesser Martin M   Benkert Steven S   Waters Cory C   Ruitenberg Joyce J   Bellman Paul P  

PLoS clinical trials 20070126 1


<h4>Objectives</h4>To determine whether immunotherapy of chronic HIV-1 infection can prevent or attenuate viremia upon antiviral discontinuation.<h4>Design</h4>This was a Phase II randomized, partially double blinded, 2x2 factorial study of three steps of 12 wk/step. Step I involved four groups: (1) vaccine placebo, (2) vaccine (ALVAC, vCP1452), (3) placebo + interleukin 2 (IL-2), and (4) vaccine + IL-2. Step II involved a 12-wk diagnostic treatment interruption (DTI). Step III involved an exten  ...[more]

Similar Datasets

| S-EPMC5707888 | biostudies-literature
| S-EPMC5953386 | biostudies-literature
| S-EPMC8367093 | biostudies-literature
2015-10-01 | GSE37025 | GEO